# A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

> **NCT03002974** · PHASE2 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 165 (actual)

## Conditions studied

- Acute Gouty Arthritis

## Interventions

- **DRUG:** Anakinra 100 mg
- **DRUG:** Triamcinolone Acetonide 40 mg
- **DRUG:** Placebo to Anakinra 100 mg
- **DRUG:** Placebo to Triamcinolone Acetonide 40 mg

## Key facts

- **NCT ID:** NCT03002974
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-06
- **Final completion:** 2019-08
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002974, "A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03002974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*